Laparoscopic living donor right hepatectomy regarding the anatomical variation of portal vein: A propensity Score Matched Analysis

2021 ◽  
Author(s):  
Jinsoo Rhu ◽  
Mi Seung Kim ◽  
Gyu‐Seong Choi ◽  
Jong Man Kim ◽  
Choon Hyuck David Kwon ◽  
...  
Keyword(s):  
Propensity Score ◽  
Portal Vein ◽  
Living Donor ◽  
Anatomical Variation ◽  
Right Hepatectomy

scholarly journals Pure laparoscopic versus open living donor right hepatectomy using a propensity score matched analysis: challenge to 0% of complication

HPB ◽  
2019 ◽  
Vol 21 ◽  
pp. S187-S188
Author(s):  
H.D. Cho ◽  
K.H. Kim ◽  
Y.I. Yoon ◽  
S.K. Lee ◽  
D.H. Jung ◽  
...  
Keyword(s):  
Propensity Score ◽  
Living Donor ◽  
Right Hepatectomy

One‐Year Recipient Morbidity of Liver Transplantation Using Pure Laparoscopic Versus Open Living Donor Right Hepatectomy: Propensity Score Analysis

2019 ◽  
Vol 25 (11) ◽  
pp. 1642-1650 ◽  
Author(s):  
Jungchan Park ◽  
Choon Hyuck David Kwon ◽  
Gyu‐Seong Choi ◽  
Suk‐Koo Lee ◽  
Jong Man Kim ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Propensity Score ◽  
Living Donor ◽  
Propensity Score Analysis ◽  
Right Hepatectomy ◽  
Score Analysis ◽  
One Year

Measurement of liver volumes by portal vein flow by Doppler ultrasound in living donor liver transplantation

2017 ◽  
Vol 31 (9) ◽  
pp. e13050 ◽  
Author(s):  
Sang Hyun Choi ◽  
Jae Hyun Kwon ◽  
Kyoung Won Kim ◽  
Hye Young Jang ◽  
Ji Hye Kim ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Portal Vein ◽  
Doppler Ultrasound ◽  
Living Donor ◽  
Living Donor Liver Transplantation ◽  
Donor Liver ◽  
Donor Liver Transplantation ◽  
Portal Vein Flow

scholarly journals Oncological Outcomes after Liver Venous Deprivation for Colorectal Liver Metastases: A Single Center Experience

Cancers ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 200
Author(s):  
Salah Khayat ◽  
Gianluca Cassese ◽  
François Quenet ◽  
Christophe Cassinotto ◽  
Eric Assenat ◽  
...  
Keyword(s):  
Portal Vein ◽  
Liver Metastases ◽  
Portal Vein Embolization ◽  
Colorectal Liver Metastases ◽  
Future Liver Remnant ◽  
Small Sample ◽  
Right Hepatectomy ◽  
Liver Remnant ◽  
Oncological Outcomes ◽  
Extended Right Hepatectomy

Colorectal liver metastases (CRLM) are the major cause of death in patients with colorectal cancer (CRC). The cornerstone treatment of CRLM is surgical resection. Post-operative morbidity and mortality are mainly linked to an inadequate future liver remnant (FLR). Nowadays preoperative portal vein embolization (PVE) is the most widely performed technique to increase the size of the future liver remnant (FLR) before major hepatectomies. One method recently proposed to increase the FLR is liver venous deprivation (LVD), but its oncological impact is still unknown. The aim of this study is to report first short- and long-term oncological outcomes after LVD in patients undergoing right (or extended right) hepatectomy for CRLM. Seventeen consecutive patients undergoing LVD between July 2015 and May 2020 before an (extended) right hepatectomy were retrospectively analyzed from an institutional database. Post-operative and follow-up data were analyzed and reported. Primary outcomes were 1-year and 3-year overall survival (OS) and hepatic recurrence (HR). Postoperative complications occurred in 8 patients (47%). No deaths occurred after surgery. HR occurred in 9 patients (52.9%). 1-year and 3-year OS were 87% (95% confidence interval [CI]: ±16%) and 60.3%, respectively (95% CI: ±23%). Median Disease-Free Survival (DFS) was 6 months (CI 95%: 4.7–7.2). With all the limitations of a retrospective study with a small sample size, LVD showed similar oncological outcomes compared to literature reports for Portal Vein Embolization (PVE).

scholarly journals Chemoembolization Plus Radiotherapy versus Chemoembolization Plus Sorafenib for the Treatment of Hepatocellular Carcinoma Invading the Portal Vein: A Propensity Score Matching Analysis

Cancers ◽  
2020 ◽  
Vol 12 (5) ◽  
pp. 1116 ◽  
Author(s):  
Hee Ho Chu ◽  
Jin Hyoung Kim ◽  
Ju Hyun Shim ◽  
Sang Min Yoon ◽  
Pyeong Hwa Kim ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Propensity Score ◽  
Portal Vein ◽  
Propensity Score Matching ◽  
Combined Treatment ◽  
Correct Selection ◽  
Advanced Hepatocellular Carcinoma ◽  
Entire Study ◽  
Treatment Type ◽  
Significant Difference

A combination of transarterial chemoembolization (TACE) plus sorafenib or radiotherapy (RT) has demonstrated efficacy in patients with advanced hepatocellular carcinoma (HCC). Here, the two combined treatment approaches were compared in patients with HCC and portal vein tumor thrombus (PVTT). Data from 307 patients treated with TACE plus RT (n = 203) or TACE plus sorafenib (n = 104) as first-line treatment for HCC with PVTT were retrospectively evaluated. Using the propensity model to correct selection bias, 87 patients were included from each treatment group. During follow up (median, 12 months) in the entire study population, the median progression-free survival (PFS) and overall survival (OS) were significantly longer in the TACE plus RT group than in the TACE plus sorafenib group (6.5 vs. 4.3 months, respectively; p = 0.017 and 16.4 vs. 12 months, respectively; p = 0.007). Following propensity score matching, the median PFS and OS in the two groups showed no statistically significant difference. Multivariable analysis found no significant association between PFS or OS and the treatment type. In conclusion, this retrospective study of data from patients with advanced HCC with PVTT shows that PFS and OS did not differ significantly in patients treated with TACE plus RT and TACE plus sorafenib.

Sign in / Sign up

Export Citation Format

Share Document